
Johnson & Johnson: AI analysis
$270.47+1.25% today
Johnson & Johnson: steady growth, but the stock asks for a lot
Johnson & Johnson is still a two-engine healthcare business: Innovative Medicine and MedTech. The case for owning it at this price depends on that mix keeping compound growth alive while margins stay near their recent high and the market keeps rewarding its quality. The problem is that the share price already assumes growth far faster than the company has delivered from 2020 to 2025.
The verdict
Earns far more than most companies on the money it uses.
The price assumes much faster growth than the company has ever shown.
Some things could go wrong; none look urgent.
Strong protection from competitors.
Written by AI on Nov 8, 2026 from company filings and prices to Nov 6, 2026.
Figures as of Nov 6, 2026, the prices this analysis used. The share price is down 2.1% since ($270.47 now); the stock page shows today's figures.
Read the full analysis
Create a free account to read 3 AI analyses a month: the business, its moat, growth, profits, balance sheet, what the price expects, both cases and what to watch. Pro unlocks every analysis.